CT47A11: A Potential Drug Target and Biomarker for Cancer and Testis Antigens

Target Name: CT47A11

NCBI ID: G255313

CT47A11

CT47A11: A Potential Drug Target and Biomarker for Cancer and Testis Antigens

CT47A11 is a protein that is expressed in a variety of tissues, including the brain, spleen, and Peyer's patches of the small intestine. It is also highly expressed in cancer cells, making it an attractive target for cancer therapies. In addition, CT47A11 is also expressed in testes, which makes it a potential biomarker for testicular cancer.

The molecules that make up CT47A11 have unique structural features that give them unique properties. One of the most notable is their ability to interact with a variety of different molecules, including cytokines and cancer-associated antigens (CAATs). This ability to interact with a wide range of molecules makes CT47A11 an attractive target for drug development.

Drugs that target CT47A11 have the potential to be used for a variety of different treatments, including cancer and testicular cancer. One of the most promising of these drugs is a monoclonal antibody (MAb) called Adalimumab (ado-trastuzumab emtansine), which is currently being tested for the treatment of breast and ovarian cancer.

In addition to its potential as a drug target, CT47A11 is also a potential biomarker for cancer and testicular cancer. Its high expression in cancer cells makes it a useful marker for tracking disease progression and responding to treatment. In addition, its expression in testes makes it a potential indicator of the effectiveness of a treatment.

The Structure of CT47A11

CT47A11 is a type of transmembrane protein that is expressed in a variety of tissues throughout the body. It is characterized by a long extracellular domain that is made up of multiple domains, including a catalytic domain, a transmembrane domain, and an intracellular domain. The catalytic domain is responsible for the catalytic activity of CT47A11, which is its ability to interact with a wide range of different molecules.

The transmembrane domain is responsible for the protein's ability to interact with other molecules on the surface of cells. It is composed of multiple domains, including a transmembrane domain and an intracellular domain. The intracellular domain is responsible for the protein's ability to interact with inside the cell.

The ability of CT47A11 to interact with a wide range of different molecules makes it an attractive target for drug development. Its catalytic domain allows it to interact with a variety of different molecules, including cytokines and cancer-associated antigens (CAATs). This ability to interact with a wide range of different molecules makes CT47A11 an attractive target for the development of antibodies or other drugs that can inhibit its activity.

Expression of CT47A11 in Cancer Cells

CT47A11 is highly expressed in cancer cells, making it an attractive target for cancer therapies. Its high expression in cancer cells makes it a useful marker for tracking disease progression and responding to treatment. In addition, its expression in cancer cells makes it a potential indicator of the effectiveness of a treatment.

For example, studies have shown that high levels of CT47A11 expression are associated with poor prognosis in breast cancer. In addition, high levels of CT47A11 expression have also been observed in ovarian cancer, making it an potential biomarker for this type of cancer.

Expression of CT47A11 in Testes

In addition to its expression in cancer cells, CT47A11 is also highly expressed in testes. This makes it a potential biomarker for testicular cancer,

Protein Name: Cancer/testis Antigen Family 47 Member A11

The "CT47A11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CT47A11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets